Cybin

HELP Lead: Phase 3 12 Biotech Distilled articles ↓

Catalyst timeline

HLP003 Ph3 topline4Q 2026HLP003 Ph3 topline, 4Q 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

CYB003

HLP003

Small Molecule Target: serotonin 5-HT2A receptor

Major Depressive Disorder Phase 3 oral NCT05385783

CYB003

Small Molecule Target: serotonin 5-HT2A receptor

Alcohol Use Disorder Phase 2

CYB004

HLP004

Small Molecule Target: serotonin 5-HT2A receptor

Generalized Anxiety Disorder Phase 2 NCT06051721

Discontinued (1)

SPL026 — Major Depressive Disorder

Biotech Distilled coverage (12)

2026-08-15 UPDATE: Helus Pharma (HELP) - A Permanent CEO, a Clean DDI Study, and 11 Million New Shares 🔒 Paid
2026-07-21 UPDATE: Helus Pharma (HELP) - APPROACH Enrollment Done, The Binary Event Is Now a Data Question 🔒 Paid
2026-06-29 UPDATE: Helus Pharma (HELP) - The +35% Rip, the Definium Footnote, and EMBRACE Enters the Chat 🔒 Paid
2026-06-24 UPDATE: Helus Pharma (HELP) - The Dilution Lands, And It’s Not the ATM 🔒 Paid
2026-05-16 UPDATE: Helus Pharma (HELP) - Point72 Trims, Sirenia Arrives, Stock Bleeds 🔒 Paid
2026-04-27 UPDATE: Helus Pharma (HELP) - Cola Gets the Boot, Trump Signs the EO, Millennium Doubles Down 🔒 Paid
2026-03-28 UPDATE: Helus Pharma (HELP) - Izzy Englander Buys the Dip 🔒 Paid
2026-03-07 UPDATE: Helus Pharma (HELP) - The Pooled Data Trick and the $5.25 Reality Check 🔒 Paid
2026-02-28 UPDATE: Helus Pharma (HELP) - The Big Pharma Makeover is Complete 🔒 Paid
2026-02-21 UPDATE: Helus Pharma (HELP) - The Smart Money Tug-of-War & Peer-Reviewed Receipts 🔒 Paid
2026-02-14 UPDATE: Helus Pharma (HELP): The Big Guns Arrive 🔒 Paid
2026-01-16 Helus Pharma (HELP), formerly Cybin (CYBN): Scientific Deep Dive for HLP003 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.